Urologists continue to push the limits of minimally invasive surgery, and key papers presented at the AUA meeting will explore the functional and cancer control outcomes associated with minimally invasive and robotic procedures in prostate cancer and renal cell carcinoma. When to use such approaches remains a source of controversy.
Drugs and devices in the pipeline from Astellas Pharma, Medivation, Repros Therapeutics, Metamark Genetics, Argos Therapeutics, S1 Biopharma, Ipsen, Sprout Pharmaceuticals, Antigen Express, Generex Biotechnology, Veloxis Pharmaceuticals, and Absorption Pharmaceuticals.
A study from Memorial Sloan-Kettering Cancer Center, New York sheds light on the “obesity paradox” seen with renal cell carcinoma while at the same time demonstrating the emerging value of genomics in understanding cancer and other diseases.
The take-home message is that for sorafenib and sunitinib, sequencing does not appear to be drug dependent and either can be used as first- or second-line therapy.
The sequential use of two targeted treatments for metastatic renal cell carcinoma appears to yield similar total progression-free survival regardless of the order in which they are given, phase III study results indicate.
Prostate cancer has made its way into another set of Choosing Wisely recommendations, this time from the American Society of Clinical Oncology.
The tyrosine kinase inhibitors pazopanib (Votrient) and sunitinib (Sutent) had similar benefits in delaying progression of advanced renal cell carcinoma, but the safety profile and many measures of quality of life favored pazopanib, according to data from a recently published multicenter study.
Andrew Wagner, MD, presents the take home messages on kidney cancer from the AUA annual meeting in San Diego.
AVEO Oncology recently announced that it has received a complete response letter from the FDA informing the company that the FDA will not approve in its present form the new drug application for AVEO’s investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
Physicians and patients alike may not be aware of the benefits of nephron-sparing surgical methods, according to a recent study.